Sotorasib Provides Durable Clinical Benefit for Patients with NSCLC and KRAS Mutations
Exciting New Research to be Presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer’s Presidential Symposium SINGAPORE, Jan. 28, 2021 (GLOBE NEWSWIRE) — In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) […]